Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Virtu Financial LLC

Key Points

• Virtu Financial LLC significantly reduced its holdings in Hims & Hers Health, Inc. by 50.6%, selling 69,907 shares during the first quarter.
• Insider transactions include CEO Andrew Dudum selling 128,127 shares, marking a 44.44% decrease in his stake, while CFO Oluyemi Okupe sold 23,107 shares, a 26.77% decrease in his ownership.
• Hims & Hers reported earnings of $0.17 EPS for the last quarter, missing analysts' expectations, with a revenue growth of 72.6% year-over-year.

Virtu Financial LLC decreased its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 50.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 68,198 shares of the company's stock after selling 69,907 shares during the quarter. Virtu Financial LLC's holdings in Hims & Hers Health were worth $2,015,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Allworth Financial LP raised its position in shares of Hims & Hers Health by 20.0% in the 1st quarter. Allworth Financial LP now owns 2,006 shares of the company's stock worth $56,000 after acquiring an additional 334 shares in the last quarter. Signaturefd LLC grew its stake in Hims & Hers Health by 17.7% in the first quarter. Signaturefd LLC now owns 2,586 shares of the company's stock valued at $76,000 after purchasing an additional 388 shares during the last quarter. Larson Financial Group LLC raised its holdings in Hims & Hers Health by 47.7% in the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock worth $42,000 after purchasing an additional 458 shares in the last quarter. Summit Investment Advisors Inc. lifted its position in shares of Hims & Hers Health by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company's stock valued at $480,000 after buying an additional 628 shares during the last quarter. Finally, Cim LLC lifted its position in shares of Hims & Hers Health by 1.0% during the fourth quarter. Cim LLC now owns 71,869 shares of the company's stock valued at $1,738,000 after buying an additional 694 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health Trading Up 0.8%

Shares of HIMS traded up $0.38 on Wednesday, hitting $48.34. 19,171,239 shares of the stock traded hands, compared to its average volume of 34,181,773. Hims & Hers Health, Inc. has a 1 year low of $13.47 and a 1 year high of $72.98. The stock's 50 day moving average is $53.39 and its two-hundred day moving average is $45.30. The firm has a market capitalization of $10.82 billion, a P/E ratio of 60.43, a P/E/G ratio of 3.16 and a beta of 2.08. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $544.83 million for the quarter, compared to analysts' expectations of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm's quarterly revenue was up 72.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.06 earnings per share. As a group, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Bank of America upped their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a report on Tuesday, April 29th. Piper Sandler reaffirmed a "neutral" rating and issued a $39.00 price target (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Wall Street Zen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Truist Financial upped their target price on Hims & Hers Health from $45.00 to $48.00 and gave the company a "hold" rating in a research report on Thursday, July 17th. Finally, Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $39.83.

Insider Buying and Selling

In other news, CEO Andrew Dudum sold 660,000 shares of the firm's stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the completion of the sale, the chief executive officer directly owned 2,214,769 shares in the company, valued at $112,023,016.02. This trade represents a 22.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Soleil Boughton sold 2,572 shares of the stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $51.64, for a total value of $132,818.08. Following the completion of the transaction, the insider directly owned 153,021 shares of the company's stock, valued at $7,902,004.44. This represents a 1.65% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,460,276 shares of company stock valued at $77,374,454 in the last 90 days. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.